The possibility of using IHC in lieu of the FISH assay in cases of NB seems to be a potentially useful strategy and cost-effective solution in a resource-limited setting, particularly in regions of the world where the incidence of MYCN-amplified NB is higher, such as in the Middle East.3 Furthermore, the potential influence of the patient’s genetic background on the phenotype of their tumors made us choose to investigate the correlation between the MYCN gene FISH results and IHC protein expression levels in two ethnically distinct groups of patients (MED and NAD). This evidence concerns the gene MYCN and neuroblastoma.